QUALITY OF LIFE OF CHRONIC KIDNEY DISEASE PATIENTS WITH ROUTINE HEMODIALYSIS IN GENERAL HOSPITALS IN SLEMAN YOGYAKARTA

Sihombing J,Irijanto F,Andayani T M,Hakim L

doi:10.22159/ijpps.2017v9i2.15844

Abstract

Objective: To elicit quality of life (QOL) of chronic kidney disease (CKD) patients with routine hemodialysis receiving erythropoietin, to compare the QOL of CKD patients with routine hemodialysis receiving different erythropoietin, and to explore the change in QOL over six months for patients managed in the hospitals.Methods: A multicenter prospective study was conducted among adult CKD patients in Yogyakarta. QOL was measured using kidney disease quality of life–short form (KDQOL–SFTM) questionnaire and a FACIT fatigue scale questionnaire. CKD patients were divided into 2 groups: those receiving erythropoietin alpha (n=74) and those receiving erythropoietin beta (n=39). Both groups were asked to complete the KDQOL–SFTM questionnaire and a FACIT fatigue scale questionnaire two times in six months range.Results: In the first period, the average rate of the KDQOL-SF and FACIT for CKD patients receive erythropoietin alpha compared to CKD patients receive erythropoietin beta was 77.24: 80.21 and 3.35: 3.49 while in the second period, the average rate of the KDQOL-SF and FACIT for CKD patients receive erythropoietin alpha compared to CKD patients receive erythropoietin beta was 80.45: 83.95 and 3.45: 3.56.Conclusion: Erythropoietin can improve QOL of CKD patients with routine hemodialysis, while erythropoietin beta gives more improvement, but statistically, it doesn’t different significantly.

Highlights

chronic kidney disease (CKD) prevalence in all over the world predicted to reach 8–16% of the populations
Participants were eligible if they were CKD patients with routine hemodialysis at least in three months, aged from 20–80 y and use EPO to treat their anemia
The average rate of Functional Assessment Chronic Illness Therapy (FACIT) for CKD patients receives erythropoietin alpha compared to CKD patients receive erythropoietin beta was 3.35: 3.49 while in the second period, the average rate of FACIT for CKD patients receives erythropoietin alpha compared to CKD patients receive erythropoietin beta was 3.45: 3.56

Summary

Introduction

CKD prevalence in all over the world predicted to reach 8–16% of the populations. CKD incidence rises every year, especially in developing countries cause of increasing life expectation age, so that people have a longer age. CKD therapy needs special treatment such as dialysis (hemodialysis or peritoneal dialysis) or renal transplantation which needs a lot of costs. Renal transplantation is more efficient compared to dialysis because only in one treatment can make patients avoid dialysis procedure which takes place in relatively long duration. Many people use dialysis to treat CKD [1]. It said that almost 50% CKD stage 3–4 patients have anemia and increase almost 75% in end-stage renal disease (ESRD) [2]

Methods

Results

Discussion

Conclusion